Dedicated to quality and driven by excellence, we are committed to improving the lives of patients worldwide. We are steadfast in our goal to develop innovative cellular therapies that bring us closer to a cure.
From the very beginning, we’ve been focused on science. We came together
as a team of experts dedicated to quality, driven by excellence, and committed
to experimentation. Though we faced many challenges, we remain fearless in
our research and rigorous in our thinking, pushing ourselves to work harder.
At Legend Biotech, we have the opportunity to change the way treatments are developed across diseases and continents. Our goal is to reinvigorate treatment approaches in oncology and beyond.
The spark of hope is lit and we’re using that hope to ignite the future of cell therapy!
We welcome the opportunity to reinvigorate the treatment approaches in oncology and the future of cell therapy.
Today, our research is focused on continuous innovation in the field of cell therapy.
We are also future-focused on emerging technologies that can help address
some of the most chronic and life-threatening diseases.
Our goal is to reimagine healthcare and to deliver transformative treatments.
And at Legend Biotech, that’s what we’re doing every day.
Our driving force at Legend Biotech is sharing our passion for developing cutting-edge cell therapies with our colleagues and the healthcare community. We do that by being:
Efficient: We constantly look for inspiration inside
and outside the world of cell therapy.
Transparent: We work openly and collaboratively to establish trust and protect the relationships we’ve developed over time.
Passionate: We have an innate drive for scientific advancement in order to bring the power of cell therapies to patients.
Fearless: We focus on the importance of continuous learning and intellectual humility, using these attributes to advance to the next step.
Accountable: Be reliable and dependable; do what you say you will do. This idea is at the core of what we believe.
Legend Biotech has entered into a worldwide collaboration and
license agreement with Janssen Biotech, Inc., one of the Janssen
Pharmaceutical Companies of Johnson & Johnson, to develop,
manufacture, and commercialize LCAR-B38M (JNJ-68284528/JNJ-4528).
Under the terms of the agreement, Legend and Janssen are co-developing and will
Legend received clearance from China National Medical Products Administration in March 2018 for a Phase 2 registration study in China, and Janssen Biotech, Inc. received US Food and Drug Administration clearance for an Investigational New Drug Application in May 2018 and has since initiated a Phase 1b/2 study intended for registration in the United States and EU.
JNJ-4528 was granted Orphan designation by the US FDA in February 2019 followed by PRIME designation in the EU by the EMA in April 2019.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
*LCAR-B38M identifies the investigational product being studied in China and Janssen Biotech, Inc.'s JNJ-68284528 (also referenced as JNJ-4528) identifies the investigational product being studied in the United States, both of which are representative of the same CAR-T cell therapy.
At Legend Biotech, we are transforming the world of oncology and medicine, and always looking for people who can help contribute to the strength of our team and to our shared values.
We are actively hiring across multiple functions and levels to strengthen our world-class team with our goal and commitment to improving patients' lives through transformative science and medicine.
To view and apply for one of our current open positions,
You are about to leave LegendBiotech.com.
Are you sure you want to leave so soon?